Live Breaking News & Updates on Viamet Pharmaceuticals Holdings

Stay updated with breaking news from Viamet pharmaceuticals holdings. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights


Press release content from Business Wire. The AP news staff was not involved in its creation.
PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
March 15, 2021 GMT
MALVERN, Pa. & SAN DIEGO (BUSINESS WIRE) Mar 15, 2021
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and provided an update on clinical trial activities.
ADVERTISEMENT
“Throughout 2020, PhaseBio made significant progress advancing our pipeline of therapies for serious cardiopulmonary diseases,” said Jonathan P. Mow, Chief Executive Officer of PhaseBio Pharmaceuticals. “Our progress was driven by the continued global expansion of the pivotal Phase 3 REVERSE-IT trial of our lead product candidate bentracimab, whi ....

San Diego , United States , John Sharp , Alexc Sapir , Phasebio Pharmaceuticals Inc , Pulmonary Vascular Research Institute , Selenity Pharmaceuticals Bermuda Ltd , Canale Communications Inc , European Union , Committee For Medicinal Products Human Use , Development Collaboration , Viamet Pharmaceuticals Holdings , Drug Administration , World Congress On , Bentracimab Clinical Development Plan , Exchange Commission , Phasebio Pharmaceuticals , European Medicines Agency , Bentracimab To Support Development , Chief Executive Officer , Biologics License Application , Supply Agreement , Support Development , Dosed First Patients , Intervention Trial , Written Scientific Advice ,

Candidiasis Therapeutics Market Insights, Trends, Size, Share and Forecast 2020 – 2027 | Key Players – Biomar Microbial Technologies, Merck ,Scynexis Inc. – KSU


Come and apply the insights recommended by the honchos of the
Candidiasis Therapeutics industry.
 
Candidiasis Therapeutics Market Report, published by Decisive Markets Insights, provides granular information & analysis on the size, share, growth patterns, segment and forecast of the market from, 2020 – 2027.The report covers the rapidly evolving market scenario and the current and future evaluation of their impact on the overall industry along with regional coverage across the globe. With an in-depth report on sales growth and profitability, it also covers the accurate trend and analysis that would impact the market in the coming years. The analysis provides key players, a competitive perspective so as to formulate their business strategies accordingly. ....

United States , United Kingdom , South Korea , Terbinafine Daskil , Asia Pacific , Flucytosine Ancobon , Sunil Kumar , Grupo Ferrer Internacional , Bayer Ag , Amplyx Pharmaceuticals Inc , Viamet Pharmaceuticals Holdings , Scynexis Inc , Basilea Pharmaceutica Ltd , Key Company Profiles , Astellas Pharma Inc , Novadigm Therapeutics Inc , Mycovia Pharmaceuticals Inc , Extensive Research Methodology , Key Companies , Decisive Markets Insights , Candidiasis Therapeutics , Therapeutics Market Report , Sample Copy , Companies Operating , Ferrer Internacional , Pharmaceuticals Holdings ,